Funxional Therapeutics Co

Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT’s focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed the Phase I studies in the USA and is ready for “gold standard” three month Phase II studies in major inflammatory conditions, planned to start during 1H 2011. Attractive efficacy compared to existing therapeutic options, together with a clean safety profile, dosing convenience and low cost all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major diseases such as asthma/COPD, RA, acne, psoriasis and IBD.

FXT's two proprietary technologies were originated within Cambridge University and include:

•             the somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma and rheumatoid arthritis. FXT’s portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimized for topical, parenteral and oral delivery.

•             G-protein coupled receptors Agonist-Enriched Libraries (GAEL), which are able to identify novel small molecules with potentially exciting pharmacologic profiles.